- 主辦 / 主持人
- 台灣肺癌學會
- 積分
- B類 4 分
- 分類
- 未分類
- 聯絡人
- 台灣肺癌學會 02-28289897
- 活動日期
- 2026-08-16 (日) 08:30 ~ 12:50
- 地點
- 台北喜來登B2
- 說明
- This forum aims to review and look ahead at advancements in lung and gastrointestinal (hepatocellular carcinoma) cancer care, helping physicians optimize clinical decision-making and improve patient outcomes through multidisciplinary scientific exchange. In Non-Small Cell Lung Cancer (NSCLC), the forum explores real-world evidence for first-line PD-L1 agnostic strategies, balancing efficacy with treatment burden in high PD-L1 expression patients, and tailoring immunotherapy regimens for elderly and frail populations, which helps physicians personalize treatments for diverse patient profiles while minimizing toxicity and treatment burden; for Small Cell Lung Cancer (SCLC), by examining the latest clinical evidence and frontier regimens across limited-stage and extensive-stage disease, it assists physicians in establishing clear daily management pathways to extend survival for patients facing this challenging prognosis; regarding KRAS-mutated lung cancer (e.g., KRAS-G12C), deep dives into molecular mechanisms and novel targeted drug developments help physicians break through traditional second-line treatment bottlenecks and offer patients more precise, targeted options; and in unresectable Hepatocellular Carcinoma (uHCC) and GI cancers, the forum focuses on a decade of experience with PD-L1 + VEGF dual blockade, balancing oncologic response with functional liver reserve, and integrating multimodal strategies—such as external radiotherapy and Y90 radioembolization combined with systemic therapy—enabling physicians to flexibly design comprehensive care plans that effectively control liver tumors while preserving patients' liver function and quality of life.
2026-08-16 台北喜來登B2
| 時間 | 主題 | |
|---|---|---|
| 沒有資料 | ||